Rigel Pharmaceuticals Inc. (RIGL) exhibits 93.3% gross margins and 28.2% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 7.3x enterprise multiple and 4.8% implied options volatility.
Sustained 93.3% gross profitability converts into 42.6% operating margin and 28.2% ROIC, outpacing sector cost of capital.
ROIC: 28.2% // GM: 93.3%YoY revenue trajectory of +64.1% paired with 7.87% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +64.1% // FCF YLD: 7.87%Altman Z-Score of 3.64 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.64 // F-SCORE: 7/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 7.3xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $51.45 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 68.0% net margins.
NET MARGIN: 68.0% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for RIGL & activate live FRED threshold breach alerts.